{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-043431","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2026-06-16T12:39:37+00:00","discovered_at":"2026-06-16T12:45:00.298759+00:00","generated_at":"2026-06-16T12:45:08.695208+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GeneDx names Mark Gardner as President, effective June 15, 2026","bullets":["Mr. Gardner, former Quest Diagnostics SVP, will oversee lab and commercial ops, reporting to CEO Katherine Stueland.","Compensation includes $530K base salary, 65% target bonus, and $2M RSU grant vesting over four years.","Bryan Dechairo transitions to lead product, technology and innovation initiatives.","Gardner previously served as CEO of OmniSeq and held senior roles at Thermo Fisher Scientific and Life Technologies."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-043431","json":"https://secwatch.observer/filing/0001628280-26-043431.json","markdown":"https://secwatch.observer/filing/0001628280-26-043431.md","text":"https://secwatch.observer/filing/0001628280-26-043431.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000162828026043431/0001628280-26-043431-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000162828026043431/wgs-20260615.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T12:45:08.695208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62ea44dd02","claim":"Bryan Dechairo changed role as other at GeneDx Holdings Corp..","evidence_excerpt":"Following Mr. Gardner’s appointment, Bryan Dechairo will transition into a role focused on leading the Company’s product, technology and innovation initiatives.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000162828026043431/0001628280-26-043431-index.htm","confidence":0.65,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"}],"fact_type":"executive_change"},{"claim_id":"b72bbad206","claim":"Mark Gardner was appointed as President at GeneDx Holdings Corp..","evidence_excerpt":"On June 16, 2026, GeneDx Holdings Corp. (the “Company”) announced the appointment of Mark Gardner, age 60, in the role of President, which was effective on June 15, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000162828026043431/0001628280-26-043431-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}